The New Part D: "Dollars for Donuts" Becomes Discounts For Data
This article was originally published in RPM Report
Executive Summary
The pharmaceutical industry's 50% donut hole discount worked out exactly as planned in the context of shaping the health care reform debate. The implementation of the new program is a different story. The program created by CMS doesn't look anything like industry would have hoped-but manufacturers have no choice but to play by CMS' rules, and try to make it work for them anyway.
You may also be interested in...
Defense-to-Offense: PhRMA Readies to Protect Government Markets
White House budget targeting biopharma with new cuts hits just as the Pharmaceutical Research & Manufacturers of America’s annual meeting gets under way.
"Dollars for Donuts" Deal Revisited: What Pharma Got
A Kaiser Family Foundation report on the impact of the Medicare Part D donut hole reads like an artifact of history. But it helps quantify the benefit to brand name industry from closing the donut hole in the context of health care reform.
Branding Part D: Big Changes for Biggest Plans
When it comes to Medicare Part D, the brand counts at least that’s what some of the biggest plans have concluded. From Humana/Walmart to CVS/Member Health, the drug benefit is increasingly a story of branding, both in the selling proposition to consumers and in the branding of certain plans as underperformers by CMS